AUROPHARMA:NSE-Aurobindo Pharma Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 963.70

Change

0.00 (0.00)%

Market Cap

INR 564.49B

Volume

0.55M

Avg Analyst Target

INR 1,118.78 (+16.09%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of various pharmaceutical products in India. The company primarily offers oral solids, injectables, over the counter drugs, and dietary supplements, as well as active pharmaceutical ingredients and finished dosage forms for central nervous system, cardiovascular, anti-retroviral, anti-diabetics, anti-allergies, gastroenterology, antibiotics, dermatology, respiratory, and oncology, as well as specialty generic formulations. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, transdermal patches, inhalers, vaccines, and depot injections. The company also exports its products to approximately 155 countries. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine UB-612 for India and UNICEF. Aurobindo Pharma Limited was founded in 1986 and is headquartered in Hyderabad, India. Address: Water Mark Building, Hyderabad, India, 500084

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-25 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

INR1,667.53B 57.44 31.75
DIVISLAB:NSE Divi's Laboratories Limited

N/A

INR1,280.40B 64.52 43.09
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

INR898.51B 52.28 22.27
CADILAHC:NSE Cadila Healthcare Limited

N/A

INR630.62B 29.56 20.96
LUPIN:NSE Lupin Limited

N/A

INR536.61B 44.23 20.35
ALKEM:NSE Alkem Laboratories Limited

N/A

INR406.46B 25.64 18.73
LAURUSLABS:NSE Laurus Labs Limited

N/A

INR348.25B 35.50 23.16
IPCALAB:NSE Ipca Laboratories Limited

N/A

INR279.07B 24.41 17.04
NATCOPHARM:NSE NATCO Pharma Limited

N/A

INR199.02B 45.18 26.80
AJANTPHARM:NSE Ajanta Pharma Limited

N/A

INR186.93B 28.76 17.51

ETFs Containing AUROPHARMA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.87% 27% F 15% F
Dividend Return 0.16% 13% F 5% F
Total Return 4.04% 29% F 15% F
Trailing 12 Months  
Capital Gain 18.88% 10% F 12% F
Dividend Return 0.49% 38% F 18% F
Total Return 19.37% 10% F 12% F
Trailing 5 Years  
Capital Gain 22.91% 36% F 47% F
Dividend Return 1.63% 38% F 20% F
Total Return 24.53% 36% F 46% F
Average Annual (5 Year Horizon)  
Capital Gain 12.55% 44% F 59% F
Dividend Return 0.41% 39% F 59% F
Total Return 12.95% 41% F 58% F
Risk Return Profile  
Volatility (Standard Deviation) 39.69% 69% D+ 67% D+
Risk Adjusted Return 32.63% 46% F 66% D
Market Capitalization 564.49B 94% A 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 10.58 86% B 79% C+
Price/Book Ratio 2.57 74% C 41% F
Price / Cash Flow Ratio 16.96 56% F 31% F
EV/EBITDA 6.61 88% B+ 81% B-
Management Effectiveness  
Return on Equity 27.54% 86% B 93% A
Return on Invested Capital 10.23% 43% F 69% D+
Return on Assets 8.52% 66% D 83% B
Debt to Equity Ratio 0.77% 63% D 77% C+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.79 53% F 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.